following a full submission:
ozanimod (Zeposia®) is accepted for restricted use within NHSScotland.
Indication under review: treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease as defined by clinical or imaging features.
SMC restriction: suitable for or requesting an oral treatment.
In two phase III studies, ozanimod demonstrated a significantly greater reduction in annualised relapse rate compared with another disease-modifying treatment in patients with relapsing forms of multiple sclerosis.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
- Medicine name:
- ozanimod (Zeposia)
- SMC ID:
For adult patients with relapsing remitting multiple sclerosis.
- Pharmaceutical company
- Bristol-Myers Squibb Pharmaceuticals Ltd
- BNF chapter
- Central nervous system
- Submission type
- Date advice published
- 08 February 2021